Valuation: Revance Therapeutics, Inc.

Market Cap 319M 274M 255M 234M 441M 30.48B 448M 3.01B 1.18B 15.29B 1.2B 1.17B 50.55B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 466M 435M 399M 751M 51.94B 763M 5.14B 2.01B 26.05B 2.04B 2B 86.13B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
19.01
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-78.91% 383M
+3.78%+5.37%+47.06%+3.50% 80.91B
+4.75%+26.77%-21.02%-34.67% 53.62B
+0.85%-0.32%-1.93%+30.25% 50.13B
+0.23%-1.80%+13.14%+170.56% 47.97B
+4.24%+6.08%+59.56%-15.16% 31.41B
+176.97%+173.88%+524.79%+71.60% 25.14B
+4.05%+6.38%+50.33%+100.61% 25.03B
+4.33%+7.83%+8.40%+229.37% 21.45B
+0.22%+4.68%+66.64%+127.79% 16.93B
Average +1.91%+21.01%+74.70%+60.49% 35.3B
Weighted average by Cap. +2.42%+16.78%+59.05%+53.88%

Financials

2022 2023
Net sales 133M 114M 106M 97.42M 183M 12.67B 186M 1.25B 491M 6.35B 498M 487M 21.01B 234M 201M 187M 172M 323M 22.37B 329M 2.21B 866M 11.22B 879M 860M 37.09B
Net income -356M -306M -285M -262M -493M -34.07B -501M -3.37B -1.32B -17.09B -1.34B -1.31B -56.49B -324M -278M -260M -238M -448M -30.97B -455M -3.06B -1.2B -15.53B -1.22B -1.19B -51.35B
Net Debt 77.76M 66.7M 62.29M 57.15M 107M 7.43B 109M 735M 288M 3.73B 292M 286M 12.32B 225M 193M 180M 165M 310M 21.46B 315M 2.12B 831M 10.76B 843M 825M 35.59B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock